Caricamento...
Bardoxolone methyl: drug development for diabetic kidney disease
Bardoxolone methyl activates the Keap1/Nrf2 system that plays an important role in defense responses against oxidative stress. Importantly, bardoxolone methyl has demonstrated increases in estimated glomerular filtration rate (eGFR) in patients with diabetic kidney disease (DKD) in clinical studies....
Salvato in:
| Pubblicato in: | Clin Exp Nephrol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Singapore
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7497696/ https://ncbi.nlm.nih.gov/pubmed/32594372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10157-020-01917-5 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|